肝星状细胞
依维莫司
血管生成
癌症研究
纤维化
体内
肝纤维化
药理学
医学
生物
病理
内科学
生物技术
作者
A.-C. Piguet,Syamantak Majumder,Uma Maheshwari,Reji Manjunathan,Uttara Saran,Suvro Chatterjee,Jean‐François Dufour
出处
期刊:Clinical Science
[Portland Press]
日期:2014-02-13
卷期号:126 (11): 775-791
被引量:26
摘要
Progression of liver fibrosis to HCC (hepatocellular carcinoma) is a very complex process which involves several pathological phenomena, including hepatic stellate cell activation, inflammation, fibrosis and angiogenesis. Therefore inhibiting multiple pathological processes using a single drug can be an effective choice to curb the progression of HCC. In the present study, we used the mTOR inhibitor everolimus to observe its effect on the in vitro activation of hepatic stellate cells and angiogenesis. The results of the present study demonstrated that everolimus treatment blocked the functions of the immortalized human activated hepatic stellate cell line LX-2 without affecting the viability and migration of primary human stellate cells. We also observed that treatment with everolimus (20 nM) inhibited collagen production by activated stellate cells, as well as cell contraction. Everolimus treatment was also able to attenuate the activation of primary stellate cells to their activated form. Angiogenesis studies showed that everolimus blocked angiogenesis in a rat aortic ring assay and inhibited the tube formation and migration of liver sinusoidal endothelial cells. Finally, everolimus treatment reduced the load of tumoral myofibroblasts in a rat model of HCC. These data suggest that everolimus targets multiple mechanisms, making it a potent blocker of the progression of HCC from liver fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI